Abstract:Background: Fine-needle aspiration (FNA) biopsy is typically used in conjunction with cytopathologic evaluation to differentiate between benign and malignant thyroid nodules. Even so, the cytology results for 20-30% of thyroid nodules are indeterminate. This study sought to evaluate the usefulness of next-generation sequencing (NGS)-based multi-gene panel testing for risk stratification and the differentiation of benign from malignant thyroid nodules. Methods: Thyroid nodule samples were obtained from a cohort of 359 patients who underwent FNA. An NGS-based multi-gene panel testing was conducted for these samples, in which single-nucleotide variants (SNVs) and small insertion/deletions (InDels) can be detected in 11 genes and fusion events can be identified in 5 genes. Surgical resection was conducted for 113 patients (113/359), and then histopathology results were obtained. Results: In comparison to cytology alone, the diagnostic sensitivity of NGS combination cytology increased from 0.7245 (95% CI: 0.6289-0.8032) to 0.898 (95% CI: 0.8223-0.9437); the associated AUC was 0.8303 (vs. Cytology AUC: 0.7622, P < 0.001). BRAF V600E was identified in 136 patients, of whom 79 underwent surgery and were diagnosed with papillary thyroid carcinoma (PTC) pathologically. TERT promoter mutations or BRAF / RAS co-mutations with other genes were identified in 5 patients, while 4 patients were diagnosed with malignant thyroid cancer using the pathological method. RAS mutations were identified in 27 patients, while 10 patients underwent surgery, which showed that 3 patients were classified as PTC and 7 cases were benign. In addition, 4 RET fusions, 1 RET activation mutation, and 3 TP53 inactivation mutations were identified in the remaining 8 patients who have not undergone surgery. Negative genetic test results or variants with uncertain significance were identified in 183 patients. Among these patients, 12 malignant thyroid tumors, including 11 PTC and 1 MTC, were diagnosed in 20 patients who received surgery. Conclusion: Thyroid nodules coupled with BRAF V600E , TERT promoter variants, BRAF / RAS co-mutations with other genes, RET fusions, and RET activating mutations were classified as high-risk. Nodules with RAS mutations ( NRAS , KRAS , HRAS ) and TP53 inactivating mutations were considered to be in the intermediate-risk group, while those with non-pathogenic mutations (negative and variants of uncertain significance) were placed in the low-risk group. When combined with cytopathology, NGS increases the sensitivity of diagnosing benign and malignant thyroid nodules, and the reference is useful for patient risk stratification.

A comparison of DP-TOF Mass Spectroscopy (MS) and Next Generation Sequencing (NGS) methods for detecting molecular mutations in thyroid nodules fine needle aspiration biopsies

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

Diagnostic value of contrast‐enhanced ultrasound combined with BRAF V600E mutation for cytologically indeterminate thyroid nodules

[Multi-gene mutations in ultrasound-guided fine-needle aspiration specimens of thyroid micronodules and diagnostic value in thyroid microcarcinomas using next-generation sequencing]

Diagnostic Value of BRAF (V600e)-Mutation Analysis in Fine-Needle Aspiration of Thyroid Nodules: a Meta-Analysis.

The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules

A More Sensitive Platform for the Detection of Low-Abundance Braf(V600e) Mutations

Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies

Highly Accurate NGS-based Multi-Gene Testing in the Diagnosis of Thyroid Nodules with Indeterminate Cytology.

Next-Generation Sequencing Enhances the Diagnosis Efficiency in Thyroid Nodules

Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers

Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF V600E mutation in papillary thyroid carcinoma

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

Diagnostic Performance of Next-Generation Sequencing and Genetic Profiling in Thyroid Nodules from a Single Center in China

[Clinical Role of BRAF V600E Mutation Testing in Thyroid Nodules].

Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer

Genetic alterations in cfDNA of benign and malignant thyroid nodules based on amplicon-based next-generation sequencing

Comparison of the Clinical Validity of Droplet Digital PCR to ARMS-PCR for BRAF V600E Mutation Detection in Thyroid Nodules

Detection of BRAF V600E Mutation in Fine-Needle Aspiration Fluid of Papillary Thyroid Carcinoma by Droplet Digital PCR.